IL161090A0 - Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonate, a cox-2 inhibitor and a taxol - Google Patents
Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonate, a cox-2 inhibitor and a taxolInfo
- Publication number
- IL161090A0 IL161090A0 IL16109002A IL16109002A IL161090A0 IL 161090 A0 IL161090 A0 IL 161090A0 IL 16109002 A IL16109002 A IL 16109002A IL 16109002 A IL16109002 A IL 16109002A IL 161090 A0 IL161090 A0 IL 161090A0
- Authority
- IL
- Israel
- Prior art keywords
- taxol
- cox
- inhibitor
- malignancies
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34592101P | 2001-10-19 | 2001-10-19 | |
PCT/EP2002/011696 WO2003035081A1 (en) | 2001-10-19 | 2002-10-18 | Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol |
Publications (1)
Publication Number | Publication Date |
---|---|
IL161090A0 true IL161090A0 (en) | 2004-08-31 |
Family
ID=23357099
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16109002A IL161090A0 (en) | 2001-10-19 | 2002-10-18 | Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonate, a cox-2 inhibitor and a taxol |
IL161090A IL161090A (en) | 2001-10-19 | 2004-03-25 | Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonate, a cox-2 inhibitor and a taxol |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL161090A IL161090A (en) | 2001-10-19 | 2004-03-25 | Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonate, a cox-2 inhibitor and a taxol |
Country Status (26)
Country | Link |
---|---|
US (1) | US7345088B2 (es) |
EP (1) | EP1443942B1 (es) |
JP (1) | JP2005506371A (es) |
KR (1) | KR20040066103A (es) |
CN (1) | CN100372539C (es) |
AT (1) | ATE382347T1 (es) |
AU (1) | AU2002363089B2 (es) |
BR (1) | BR0213410A (es) |
CA (1) | CA2461085A1 (es) |
CO (1) | CO5570672A2 (es) |
DE (1) | DE60224429T2 (es) |
DK (1) | DK1443942T3 (es) |
EC (1) | ECSP045054A (es) |
ES (1) | ES2301710T3 (es) |
HK (1) | HK1080733A1 (es) |
HU (1) | HUP0402061A3 (es) |
IL (2) | IL161090A0 (es) |
MX (1) | MXPA04003671A (es) |
NO (1) | NO20042056L (es) |
NZ (1) | NZ532282A (es) |
PL (1) | PL367707A1 (es) |
PT (1) | PT1443942E (es) |
RU (1) | RU2317819C2 (es) |
SI (1) | SI1443942T1 (es) |
WO (1) | WO2003035081A1 (es) |
ZA (1) | ZA200402089B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0204756D0 (en) * | 2002-02-28 | 2002-04-17 | Novartis Ag | Organic compounds |
GB0328040D0 (en) * | 2003-12-03 | 2004-01-07 | Coleman Robert E | Pharmaceutical uses of bisphosphonates |
FR2939314A1 (fr) * | 2008-12-04 | 2010-06-11 | Univ Victor Segalen Bordeaux 2 | Nouvelles compositions et methodes pour la potentialisation des signaux d'apoptose dans les cellules tumorales |
US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
WO2011014766A2 (en) | 2009-07-31 | 2011-02-03 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
WO2012071517A2 (en) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
WO2017208070A1 (en) | 2016-05-31 | 2017-12-07 | Grünenthal GmbH | Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1187130A (zh) * | 1995-06-06 | 1998-07-08 | 麦克公司 | 用二磷酸盐预防与免疫抑制疗法有关的骨损失 |
CN1398189A (zh) * | 1998-12-23 | 2003-02-19 | G.D.西尔公司 | 用于治疗肿瘤形成的放疗与cox-2抑制剂的联合治疗 |
EP1253921A4 (en) * | 2000-01-28 | 2004-10-13 | Merck & Co Inc | TREATMENT AND PROPHYLAXIS OF PROSTATE CANCER WITH COX-2 SELECTIVE INHIBITORS |
-
2002
- 2002-10-18 CA CA002461085A patent/CA2461085A1/en not_active Abandoned
- 2002-10-18 JP JP2003537648A patent/JP2005506371A/ja active Pending
- 2002-10-18 DK DK02801899T patent/DK1443942T3/da active
- 2002-10-18 PL PL02367707A patent/PL367707A1/xx not_active Application Discontinuation
- 2002-10-18 ES ES02801899T patent/ES2301710T3/es not_active Expired - Lifetime
- 2002-10-18 AT AT02801899T patent/ATE382347T1/de not_active IP Right Cessation
- 2002-10-18 NZ NZ532282A patent/NZ532282A/en unknown
- 2002-10-18 RU RU2004115337/15A patent/RU2317819C2/ru not_active IP Right Cessation
- 2002-10-18 PT PT02801899T patent/PT1443942E/pt unknown
- 2002-10-18 BR BR0213410-1A patent/BR0213410A/pt not_active IP Right Cessation
- 2002-10-18 CN CNB028207823A patent/CN100372539C/zh not_active Expired - Fee Related
- 2002-10-18 AU AU2002363089A patent/AU2002363089B2/en not_active Ceased
- 2002-10-18 EP EP02801899A patent/EP1443942B1/en not_active Expired - Lifetime
- 2002-10-18 IL IL16109002A patent/IL161090A0/xx unknown
- 2002-10-18 KR KR10-2004-7005630A patent/KR20040066103A/ko not_active Application Discontinuation
- 2002-10-18 WO PCT/EP2002/011696 patent/WO2003035081A1/en active IP Right Grant
- 2002-10-18 DE DE60224429T patent/DE60224429T2/de not_active Expired - Fee Related
- 2002-10-18 HU HU0402061A patent/HUP0402061A3/hu unknown
- 2002-10-18 US US10/493,042 patent/US7345088B2/en not_active Expired - Fee Related
- 2002-10-18 SI SI200230676T patent/SI1443942T1/sl unknown
- 2002-10-18 MX MXPA04003671A patent/MXPA04003671A/es active IP Right Grant
-
2004
- 2004-03-16 ZA ZA200402089A patent/ZA200402089B/en unknown
- 2004-03-25 IL IL161090A patent/IL161090A/en not_active IP Right Cessation
- 2004-04-08 EC EC2004005054A patent/ECSP045054A/es unknown
- 2004-04-15 CO CO04034537A patent/CO5570672A2/es not_active Application Discontinuation
- 2004-05-18 NO NO20042056A patent/NO20042056L/no not_active Application Discontinuation
-
2006
- 2006-01-18 HK HK06100803A patent/HK1080733A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2003035081A1 (en) | 2003-05-01 |
RU2004115337A (ru) | 2005-04-20 |
RU2317819C2 (ru) | 2008-02-27 |
PT1443942E (pt) | 2008-04-07 |
ZA200402089B (en) | 2005-06-22 |
BR0213410A (pt) | 2004-11-03 |
CN100372539C (zh) | 2008-03-05 |
DE60224429D1 (de) | 2008-02-14 |
CO5570672A2 (es) | 2005-10-31 |
NO20042056L (no) | 2004-05-18 |
CA2461085A1 (en) | 2003-05-01 |
ECSP045054A (es) | 2004-05-28 |
EP1443942B1 (en) | 2008-01-02 |
CN1703226A (zh) | 2005-11-30 |
MXPA04003671A (es) | 2005-06-20 |
ES2301710T3 (es) | 2008-07-01 |
US20050014726A1 (en) | 2005-01-20 |
KR20040066103A (ko) | 2004-07-23 |
HK1080733A1 (en) | 2006-05-04 |
DK1443942T3 (da) | 2008-05-19 |
HUP0402061A2 (hu) | 2005-02-28 |
NZ532282A (en) | 2006-02-24 |
US7345088B2 (en) | 2008-03-18 |
IL161090A (en) | 2010-04-15 |
EP1443942A1 (en) | 2004-08-11 |
HUP0402061A3 (en) | 2007-05-29 |
JP2005506371A (ja) | 2005-03-03 |
SI1443942T1 (sl) | 2008-08-31 |
AU2002363089B2 (en) | 2006-02-16 |
DE60224429T2 (de) | 2008-12-18 |
PL367707A1 (en) | 2005-03-07 |
ATE382347T1 (de) | 2008-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1080733A1 (en) | Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol | |
MY141584A (en) | Pharmaceutical uses of bisphosphonates | |
DE60129242D1 (de) | Verwendung von zoledronsäure zur schmerzbehandlung | |
DK1373215T3 (da) | Gelanamycinderivater egnet til behandling af cancer | |
IL157821A0 (en) | Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv | |
DE60324427D1 (de) | Verfahren zur modulation der tubulindeacetylase-aktivität | |
RS20050344A (en) | Treatment for hemorrhagic shock | |
BR0314081A (pt) | Terapia de combinação compreendendo um bisfosfonato e um inibidor de hmg-coa redutase | |
AU2003250190A1 (en) | Combination of an aromatase inhibitor with a bisphosphonate | |
GB0020504D0 (en) | Therapeutic method | |
MXPA05006722A (es) | Metodo para tratamiento de pacientes con exposicion a radiacion. | |
WO2002015894A3 (en) | Use of vitamin d derivatives as bone resorption inhibitors | |
WO2000059485A3 (en) | Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinase inhibitor | |
AU5434899A (en) | Cancer treatment | |
MXPA05013975A (es) | Tratamiento de enfermedades asociadas con amiloide y epileptogenesis. | |
TW200501958A (en) | A therapeutic agent for treating a behavioral disorder | |
BR0308105A (pt) | Composição farmacêutica compreendendo um bisfosfonato e um inibidor de cox-2 para o tratamento de doenças de ossos | |
BR0315376A (pt) | Combinações de benzotiadiazóis e inibidores de cox-2 para o tratamento de dor | |
TW200519078A (en) | 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture | |
EA200600987A1 (ru) | Применение сирамезина в лечении злокачественных опухолей | |
UA36041A (uk) | Спосіб лікування хронічного панкреатиту, ускладненого псевдокістою | |
ATE411014T1 (de) | Bakuchiol enthaltende pharmazeutische zusammensetzung zur behandlung von weiblichem brustkrebs |